1. Home
  2. Allergan, Inc Patent Portfolio Statistics

Allergan, Inc Patent Portfolio Statistics

Allergan, Inc

Allergan, Inc`s Profile

This article summarizes the perfomance of the assignee in the recent years. The overall statistics for this portfolio help to analyze the areas where the assignee is performing well. The filing trend, perfomance across the tech centers and the perfomance of the recent applications has been mentioned below. All the stats are calculated based on the perfomance in USPTO.

How does the overall patent portfolio of Allergan, Inc look like?

Total Applications: 3
Granted Patents: 2
Grant Index 66.67 %
Abandoned/Rejected Applications: 1 (33.33%)
In-Process Applications: 0
Average Grant Time: 2.96 Years
Average Office Actions: 1.5

Which Technology Area Allergan, Inc is filing most patents in? (Last 10 years)

Art Unit Definition Total Applications
1614 1
1618 Organic Compounds: Bio-affecting, Body Treating, Drug Delivery, Steroids, Herbicides, Pesticides, Cosmetics, and Drugs 1
1625 Organic Chemistry 1

How many patents are Allergan, Inc filing every year?

Year Total Applications
2022 0*
2021 0*
2020 0
2019 0
2018 0

*The drop in the number of applications filed in last two years compared to previous years is because applications can take up to 18 months to get published

Recently filed patent applications of Allergan, Inc in USPTO?

Publication number: US20210393749A1

Methods for treating urinary incontinence associated with neurogenic detrusor overactivity (NDO) and for reducing need for or frequency of clean intermittent catherization (CIC) by injecting a clostridial derivative to the bladder of a patient are disclosed.

Publication date: 2021-12-23
Applicant: Allergan, Inc
Inventors: C Cornelia Haag-Molkenteller

Publication number:


Publication date:
Applicant: Allergan, Inc
Inventors: Gregory Nicholson

Publication number: US20220023186A1

The present invention provides highly injectable, long-lasting hyaluronic acid-based hydrogel dermal filler compositions made with a di-amine or multiamine crosslinker in the presence of a carbodiimide coupling agent.

Publication date: 2022-01-27
Applicant: Allergan, Inc
Inventors: Gabriel N Njikang

How are Allergan, Inc’s applications performing in USPTO?

Application Number Title Status Art Unit Examiner
17465124 Botulinum Toxin Administration For Treatment Of Neurogenic Detrusor Overactivity Associated Urinary Incontinence Docketed New Case – Ready for Examination OPAP Central, Docket
17429237 Combination Therapy Using Clostridial Toxin Derivative And At Least One Chemical Depolarizing Agent Application Undergoing Preexam Processing 1653
17396597 Dermal Filler Compositions OPAP Central, Docket
17384388 Animal Protein-Free Pharmaceutical Compositions Response to Non-Final Office Action Entered and Forwarded to Examiner 1645 Minnifield, Nita M
17443083 Intraocular Implant With High Loading Of A Prostamide OPAP Central, Docket